Signals mentioning The Derma Co.
- Amazon Beautyverse 2026: Vitamin C searches up 35X, men's skincare grows 1.3X in India
- Sofina Ventures Trims Honasa Stake With ₹177 Cr Bulk Deal at ₹424/Share
- Sofina Ventures exits 1.28% of Honasa Consumer in ₹177 Cr bulk deal at ₹424/share
- Sofina Ventures exits 1.28% of Honasa Consumer in ₹177 Cr bulk deal at ₹424/share
- Sofina Ventures exits 1.28% of Honasa Consumer in ₹177 Cr bulk deal at ₹424/share
- Smytten opens 9th MINIS store in Hyderabad, targets 50 South India outlets by 2027
- Honasa buys 58% of Fluence Pharma at ₹135 cr, pushes Mamaearth parent into nutraceuticals
- Honasa buys 58% of Fluence Pharma for ₹135 Cr, enters nutraceuticals via Honasa Health
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000 cr nutraceuticals market
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals category
- Honasa Consumer to acquire 58% of Fluence Pharma at Rs 135 cr EV, enters Rs 16,000 cr supplements market
- Honasa Buys 58% of Fluence Pharma for ₹135 Cr, Launches Honasa Health for Nutraceuticals
- Lenskart slips 2.4% on ADIA ₹1,960 Cr exit; Honasa hits 52-week high on FY31 ₹5,500 Cr plan
- Honasa eyes ₹5,500 cr by FY31 as Q4 revenue jumps 23% and margins recover
- Honasa stock hits 52-week high as FY31 plan targets Rs 5,500 cr revenue, 300K outlets
- Honasa stock hits 52-week high as FY31 roadmap targets Rs 5,500 cr revenue, 300K outlets
- Honasa targets ₹5,500 Cr revenue by FY31, more than doubling FY26 base
- Brokerages see up to 38% upside in Honasa Consumer after Q4FY26 beat
- ICICI Securities sees 32% upside in Honasa, sets Rs 550 target on structural recovery
- Honasa Hits 52-Week High As Q4 Profit Nearly Triples, Younger Brands Drive 40%+ Growth